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2ABSTRACT24 
The LUBAC ubiquitin ligase complex, consisting of HOIL-1L, HOIP, and SHARPIN,25 
specifically generates linear polyubiquitin chains. LUBAC-mediated linear 26 
polyubiquitination has been implicated in NF-κB activation. NEMO, a component of the IκB27 
kinase (IKK) complex, is a substrate of LUBAC, but the precise molecular mechanism28 
underlying linear chain-mediated NF-κB activation has not been fully elucidated. Here, we 29 
demonstrate that linearly polyubiquitinated NEMO activates IKK more potently than30 
unanchored linear chains. In mutational analyses based on the crystal structure of the31 
complex between the HOIP NZF1 and NEMO CC2-LZ domains, which are involved in the32 
HOIP–NEMO interaction, NEMO mutations that impaired linear ubiquitin recognition33 
activity and prevented recognition by LUBAC synergistically suppressed signal-induced34 
NF-κB activation. HOIP NZF1 bound to NEMO and ubiquitin simultaneously, and HOIP 35 
NZF1 mutants defective in interaction with either NEMO or ubiquitin could not restore36 
signal-induced NF-κB activation. Furthermore, linear chain-mediated activation of IKK237 
involved homotypic interaction of the IKK2 kinase domain. Collectively, these results38 
demonstrate that linear polyubiquitination of NEMO plays crucial roles in IKK activation,39 
and that this modification involves the HOIP NZF1 domain and recognition of40 
NEMO-conjugated linear ubiquitin chains by NEMO on another IKK complex. (191/20041 
words)42 
3INTRODUCTION43 
Nuclear factor κB (NF-κB) is a family of transcription factors that play essential roles in many44 
biological phenomena, including inflammatory responses, cell survival, and innate and acquired45 
immune responses (1). Because aberrant activation of NF-κB signaling is associated with many46 
pathological conditions, such as auto-inflammatory diseases and malignancies (2, 3),47 
signal-induced activation of NF-κB has been studied extensively (4). In resting cells, inactive48 
NF-κB resides in the cytoplasm bound to its inhibitor proteins, the inhibitors of κB (IκBs).49 
Stimulation by inflammatory cytokines activates the IKK (IκB kinase) complex, composed of50 
IKK1, IKK2, and NF-κB essential modulator (NEMO). Following phosphorylation by activated51 
IKK, IκBs are degraded by the proteasome, leading to the release of NF-κB, which then52 
translocates to the nucleus to induce transcription of its target genes (5).53 
The ubiquitin-conjugation system is deeply involved in the regulation of NF-κB pathway54
(6). Recent studies showed that the LUBAC ubiquitin ligase, which specifically generates linear55 
polyubiquitin chains, is involved in NF-κB activation (7, 8). LUBAC is composed of three56 
subunits: HOIP, HOIL-1L, and SHARPIN. Patients lacking HOIL-1L and mice lacking SHARPIN57 
exhibit immunodeficiency and chronic inflammation, demonstrating the physiological significance58 
of LUBAC-mediated linear polyubiquitination (9-12). In cells from mice lacking HOIL-1L or59 
SHARPIN, the level of the residual LUBAC complex (consisting of the remaining two60 
components) is reduced, and TNF-α–induced NF-κB activation is sharply attenuated (9-12).61 
4Although NEMO is a target of linear polyubiquitination by LUBAC, it is not yet clear how linear62 
polyubiquitination of NEMO triggers IKK activation.63 
In this study, using an in vitro LUBAC-mediated IKK activation assay, we found that linear64
diubiquitin conjugation to NEMO potently induces IKK activation. We then dissected the65 
molecular mechanism underlying linear polyubiquitination of NEMO by LUBAC, and found that66 
the NPL4 zinc finger 1 (NZF1) domain of HOIP is responsible for recognition of a region in the67 
coiled-coil 2 and leucine zipper (CoZi) domains of NEMO. Mutational analyses based on a68 
co-crystal structure of HOIP NZF1 and NEMO CoZi revealed that HOIP NZF1 binds to NEMO69 
and ubiquitin simultaneously, and that both interactions are involved in linear polyubiquitination of70 
NEMO, IKK activation, and subsequent activation of NF-κB. Finally, we showed that71 
homodimerization of IKK2 is involved in linear ubiquitin chain-mediated IKK activation. Taken72 
together, our results suggest that recognition of linear polyubiquitins conjugated to NEMO,73 
possibly by NEMO in another IKK complex, triggers activation of IKK2 by trans 74 
auto-phosphorylation.75 
5MATERIALS AND METHODS 76 
 77
RT-PCR and plasmids. The open reading frames of mouse HOIP and NEMO were amplified by78 
RT-PCR of total RNA from C57BL/6 mouse liver. Other cDNAs used in this study were described79 
previously (8, 12). The following full-length proteins, deletion mutants, and fragments were80 
generated from the amplified ORF of HOIP: wild type (WT) (amino acids 1–1066), Δall-ZFs81 
(deletion of 296–432), ΔZF (deletion of 296–325), ΔNZF1 (deletion of 344–373), ΔNZF282 
(deletion of 402–432), and NZF1 (amino acids 344–382). The following proteins were generated83 
from the amplified ORF of NEMO: WT (amino acids 1–412), ΔCoZi (deletion of 250–339), and84 
ΔZF (amino acids 1–385). Mutants of HOIP (R369A, T354A, F355A, T354A/F355A), NEMO85 
(Q271A, D275A, Q271A/D275A, K278R, K302R, K278R/K302R, 86 
Q271A/D275A/K278R/K302R, F305A, E313A, Q271A/D275A/F305A, Q271A/D275A/E313A)87 
and IKK2 (V229A/H232A, Y294L/G295K/P296Q) were generated by two-step polymerase chain88 
reaction (PCR). cDNAs were ligated to the appropriate epitope-tag sequences and then cloned into89 
pcDNA3.1, pcDNA3.1-MMTV (8), pMAL-c2x (New England Biolabs), pGEX-6p1 (GE 90 
Healthcare), or MXs-IP (kindly provided by T. Kitamura). pGEX-IκBα (1–54) was described91 
previously (8). 92 
  93
Antibodies and reagents. The following antibodies were used: FLAG (M2) (Stratagene); TNFR194 
6(ab19139) (Abcam); ubiquitin (sc-8017), HA (sc-805), Glutathione S-transferase (GST) (sc-459),95 
maltose binding protein (MBP) (sc-13564), TRADD (sc-7868), and NEMO (sc-8330) (Santa Cruz 96 
Biotechnology); FLAG (F7425) (Sigma); T7 (69522) (Novagen); NEMO (K0159-3) (MBL); and97 
pIKK1/2 (#2078), RIP1 (#3493), pIκBα (#9246), and IκBα (#4812) (Cell Signaling).98 
His6-HA-Ub2, linear di- and tetra-ubiquitins and FLAG-His6-TNF-α (FH-TNF-α) were expressed99 
in E. coli. K63 diubiquitin and polyubiquitin chains (Ub1–7, Lys63-linked) were purchased from 100 
Boston Biochem. Other antibodies and reagents were generated in our laboratory, as described101 
previously (7, 8, 12). 102 
 103
Cell lines, cell cultures, and transfection. NEMO-deficient MEFs, N-1 cells (13), HEK293T 104 
cells, and HOIP Δlinear MEFs, which were established from mice that express a truncated HOIP 105 
(HOIP Δlinear) that lacks the C-terminal catalytic region, were grown in Dulbecco’s modified106 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 IU/ml penicillin,107 
and 100 μg/ml streptomycin. NEMO-deficient MEFs were kindly provided by Dr. H. Kamata108 
(Hiroshima University). NEMO-deficient MEFs stably expressing NEMO WT or mutants were109 
selected with 150 μg/ml hygromycin B (Wako) after transfection with WT or mutant110 
pcDNA3.1-MMTV-FLAG-NEMO constructs. N-1 cells stably expressing NEMO WT or mutants,111 
and HOIP Δlinear MEFs stably expressing HOIP WT, ΔNZF1, R369A, or T354A/F355A, were112 
generated using a retroviral expression system, as described previously (12); stable clones were113 
7selected with 0.2 μg/ml puromycin (Sigma-Aldrich) or 500 μg/ml G418 (Nacalai Tesque).114 
Transfections were performed using Lipofectamine 2000 (Invitrogen). 115 
 116
Immunoprecipitation and immunoblotting. Cells were lysed with lysis buffer containing 50 mM 117 
Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 2 mM PMSF, and protease inhibitor cocktail118 
(Sigma-Aldrich); lysates were clarified by centrifugation at 15,000 rpm for 20 min at 4°C. For hot119 
lysis, cells were lysed with lysis buffer containing 1% SDS in phosphate-buffered solution (PBS),120 
and then heated at 95°C for 10 min to disrupt non-covalent interactions. After heating, lysates were121 
sheared with a 25G needle and centrifuged at 15,000 rpm for 5 min at room temperature; the122 
resultant supernatant was diluted to 0.1% SDS with lysis buffer containing 50 mM Tris-HCl (pH123 
7.5), 150 mM NaCl, and 1% Triton X-100. For immunoprecipitations, lysates were incubated with 124 
the appropriate antibodies for 2 h on ice, and then immobilized on rmp–Protein A Sepharose beads125 
(GE Healthcare). The beads were washed five times with buffer containing 50 mM Tris-HCl (pH126 
7.5), 150 mM NaCl, and 1% Triton X-100. In immunoprecipitations of HA-HOIP, to digest the127 
polyubiquitin chains conjugated to NEMO, the beads were washed two more times with buffer128 
containing 50 mM HEPES-HCl (pH 7.5) and 150 mM NaCl, and then incubated with 50 μg/ml 129 
UPS2cc (kindly provided by Dr. Rohan Baker (14)) for 1 h at 37°C in buffer containing 50 mM 130 
HEPES-HCl (pH 7.5), 150 mM NaCl, and 5 mM DTT. Samples were separated by SDS-PAGE and 131 
then transferred to PVDF membranes. After blocking in Tris-buffered saline (TBS) containing132 
80.1% Tween-20 and 5% (w/v) nonfat dry milk, the membranes were incubated with the appropriate133 
primary antibodies, followed by incubation with secondary antibodies. Membranes were134 
visualized using enhanced chemiluminescence and analyzed on a LAS4000mini (Fuji Film).135 
 136
Protein expression and purification. GST-fused mouse HOIP (amino acids 344–382),137 
MBP-fused mouse NEMO (full-length), and mutants derived from either of these fusion proteins138 
were expressed in E. coli. Fusion proteins were purified using glutathione-Sepharose (GST-HOIP 139 
and derivatives) or amylose resin (MBP-NEMO and derivatives). Recombinant E1, UbcH5c,140 
His6-HOIP-HOIL-1L-Myc-SHARPIN complex, GST-IκBα (1–54), linear diubiquitin, and141 
tetra-ubiquitin were prepared, as described previously (7, 8, 15). IKK complex containing142 
HA-IKK1, IKK2, and FLAG-His6-tagged NEMO (WT or R316A/R319A/E320A) were purified143 
using the baculovirus expression system. IKK complexes were prepared from High Five cells144 
infected with appropriate combinations of baculoviruses, and the complexes were then purified on145 
Ni-nitrilotriacetic acid (Ni-NTA) agarose. After incubation with Ni-NTA agarose, bead-bound146 
proteins were treated with 100 units of calf intestinal alkaline phosphatase (New England BioLabs)147 
for 30 min at 37°C; beads were washed with ten column volumes of 5 mM imidazole; and bound148 
proteins were eluted with 300 mM imidazole.149 
For crystallization, mouse NEMO CoZi (amino acids 250–339) and human HOIP NZF1150
(amino acids 350–379) proteins were expressed and purified separately, and mixed at the proper151 
9ratio immediately before crystallization (see next section). To generate expression constructs,152 
NEMO CoZi was cloned into pGEX-4T-1 (GE Healthcare) and HOIP NZF1 was cloned into153 
pGEX-6p-1. The resultant vectors were transformed into E. coli BL21, and overexpression of the154 
GST-tagged proteins was induced by addition of 0.5 mM IPTG. After overnight incubation at 25°C,155 
cells were collected and lysed by sonication. The supernatants were applied to156 
glutathione-Sepharose 4B columns (GE Healthcare). The GST tags were cleaved using157 
thrombin/PreScission protease, and proteins were eluted from the columns with PBS buffer.158 
Further purification of the proteins was performed by gel-filtration chromatography in a buffer159 
containing 150 mM NaCl and 50 mM Tris-HCl (pH 8.0). 160 
 161
Crystallization, data collection, and structure determination of the NEMO CoZi/ HOIP 162 
NZF1 complex. Immediately before crystallization, mNEMO CoZi and hHOIP NZF1 were mixed163 
in a 2:1 molar ratio (the sequence similarity between human and mouse HOIP is illustrated in Fig.164 
3J). Co-crystals were obtained after 6 days of incubation at 20°C in 20% (w/v) PEG-3350 and 0.2165 
M DL-malic acid (pH 7.0). Single anomalous diffraction (SAD) data were collected to a resolution 166 
of 2.0 Å at the Zn atom absorption edge at a wavelength of 1.28 Å. The data were collected at 100167 
K at the beamline NW-12A of the KEK Photon Factory (Tsukuba, Japan) using HKL2000 (16), and168 
processed by iMosflm (17). Because SAD using the anomalous signal from the single zinc atom 169 
did allow successful phasing, the structure was solved by the molecular replacement (MR) method170 
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using MOLREP (18) from the CCP4 package (Collaborative Computational Project, Number 4,171 
1994). The structures of NEMO CoZi (PDB entry 3FX0) (19) and TAB2 NZF (PDB entry 2WX0)172 
(20) were used as search models for MR. One complex containing two NEMO molecules (as a173 
dimer) and one HOIP NZF1 molecule was found in each asymmetric unit of the crystal, which174 
belonged to the P65 space group. The anomalous signal from Zn atoms was used to confirm the175 
position of the Zn atom in the complex structure solved by MR. The model was further built and176 
refined using COOT (21) and REFMAC5 (22, 23). After the final refinement, NEMO CoZi amino177 
acids 252–336 and 251–337 (from the two protomers) and HOIP NZF1 amino acids 351–379 were178 
clearly visible in the electron density map. Data collection and refinement statistics are179 
summarized in Table 1. All structure figures were prepared using PyMOL (DeLano Scientific;180 
http://www.pymol.org).181 
 182
In vitro IKK activation assay. Twenty-microliter samples containing 50 mM Tris-HCl (pH 7.5), 5183 
mM MgCl2, 1 mM DTT, 2 mM ATP, 10 mM creatine phosphate, 50 μg/ml creatine phosphokinase,184 
phosphatase inhibitor cocktail (Nacalai Tesque), 5 μg/ml E1, 20 μg/ml UbcH5c, 10 μg/ml of185 
LUBAC, 5 μg/ml GST-IκBα (1–54); 250 μg/ml ubiquitin or 10, 50, or 250 μg/ml His6-HA-Ub2 186 
(Fig. 1C); and 0.5, 2.5, or 5 μg/ml (Fig. 1A) or 1 μg/ml (Figs. 1B and C) IKK complex were187 
incubated for 1 h at 30°C.188 
In Figure 1B, the first ubiquitination reaction was performed in a reaction mixture containing 50189 
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mM Tris-HCl (pH 7.5), 5 mM MgCl2, 1 mM DTT, 10 mM creatine phosphate, 50 μg/ml creatine190 
phosphokinase, 5 μg/ml E1, 20 μg/ml UbcH5c, 10 μg/ml LUBAC, and 375 μg/ml ubiquitin in the191 
presence or absence of 2 mM ATP. The reaction ran for 90 min at 30°C; after the first reaction was192 
stopped by addition of EDTA (10 mM) and DTT (5 mM), and the reaction mixture was incubated 193 
for 15 min at room temperature to release ubiquitin from E1, E2, and LUBAC. N-ethylmaleimide 194 
(NEM: 20 mM final concentration) was then added, and the reaction was incubated for 15 min at195 
room temperature to inactivate E1, E2, and LUBAC, after which DTT (10 mM final concentration) 196 
was added to inactivate excess NEM. Samples were then dialyzed against buffer containing 50 mM 197 
Tris-HCl (pH 7.5) and 5 mM MgCl2 to remove NEM, DTT, and EDTA. In the second-step reaction,198 
the dialyzed mixture containing 0.2, 1, or 5 μg of ubiquitin or linear ubiquitin chains was incubated199 
with 1 μg/ml IKK complex and 5 μg/ml GST-IκBα (1–54) in a reaction mixture containing 50 mM 200 
Tris-HCl (pH 7.5), 5 mM MgCl2, 1 mM DTT, 2 mM ATP, 10 mM creatine phosphate, and 50 μg/ml 201 
creatine phosphokinase in the presence or absence of 5 μg/ml E1, 20 μg/ml UbcH5c, and 10 μg/ml 202 
LUBAC. 203 
 204
GST and MBP pull-down assays. Five micrograms of GST-fused WT and mutant HOIP NZF1205 
proteins were immobilized on glutathione-Sepharose FF beads, and then incubated for 1 h at 4°C206 
with 1 μg of K63 diubiquitin or linear tetra-ubiquitin in buffer containing 20 mM Tris-HCl (pH 7.5), 207 
40 μM zinc chloride, 1 mM DTT, 150 mM NaCl, and 0.1% Triton X-100. The beads were washed208 
12
three times with the same buffer. 209 
Ten micrograms of MBP-fused WT and mutant NEMO proteins were immobilized on210
amylose resin, and then incubated with 1 μg of K63-diubiquitin in the presence or absence of 1 μg211 
of GST-NZF1, 5 μg of linear tetra-ubiquitin, or 1 μg of K63-Ub1-7 for 1 h at 4°C in buffer212 
containing 20 mM Tris-HCl (pH 7.5), 1 mM DTT, 150 mM NaCl, and 0.1% Triton X-100. The213 
beads were washed three times with the same buffer, boiled in SDS sample buffer, and analyzed by214 
immunoblotting. 215 
 216
In vitro ubiquitination assay. Twenty-microliter samples containing 50 mM Tris-HCl (pH 7.5), 5217 
mM MgCl2, 1 mM DTT, 2 mM ATP, 10 mM creatine phosphate, 50 μg/ml creatine phosphokinase,218 
5 μg/ml E1, 20 μg/ml UbcH5c, 0.5 μg/ml LUBAC, 1 μg/ml MBP-NEMO WT or Q271A/D275A,219 
and 50 μg/ml ubiquitin were incubated at 37°C for 1 h. The reaction mixtures were subjected to220 
immunoblotting with anti-MBP antibody. 221 
 222
Luciferase assays. HEK293T cells were transfected with pGL4.32 (Luc2p/NF-κB-RE/Hygro) and223 
pGL4.74 (hRLuc/TK) (Promega), along with expression plasmids for WT or mutant HA-HOIP,224 
Myc-HOIL-1L, and T7-SHARPIN. Twenty-four hours after transfection, cells were lysed, and225 
luciferase activities were measured on a Lumat Luminometer (Berthold) using the Dual-Luciferase226 
reporter assay system (Promega). N-1 cells were transfected with reporter plasmids, as described227 
13
above, along with pcDNA3.1-MMTV expression plasmid for WT or mutant NEMO. Sixteen hours 228 
after transfection, cells were stimulated with IL-1β (1 ng/ml) for 8 h, and luciferase activities were229 
measured as described above. 230 
 231
In vitro IKK kinase assay. NEMO-deficient MEFs stably expressing NEMO WT or 232 
Q271A/D275A were treated with TNF-α (10 ng/ml) and lysed. IKK complexes were233 
immunoprecipitated with anti-NEMO antibody. The anti-NEMO immunoprecipitates were234 
incubated with GST-IκBα (1–54) for 2 h at 30°C in kinase buffer (50 mM Tris-HCl [pH 7.5], 5 mM 235 
MgCl2, 2 mM ATP, 10 mM creatine phosphate, 50 μg/ml creatine kinase, and phosphatase inhibitor236 
cocktail). The reaction mixtures were subjected to immunoblotting with anti-pIκBα, anti-NEMO,237 
and anti-GST.238 
 239
TNFR1 immunoprecipitation. HOIP Δlinear MEFs retrovirally expressing HOIP WT, ΔNZF1,240 
R369A, or T354A/F355A were treated with FH-TNF-α (3 μg/ml); cells were lysed with lysis241 
buffer containing 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.2% NP-40, 10% glycerol, 2 mM242 
PMSF, and protease inhibitor cocktail (Sigma-Aldrich), followed by centrifugation at 10,000 × g 243 
for 20 min at 4°C. The TNFR1 complex was immunoprecipitated by incubation with 30 μl of M2244 
antibody-coupled Dynabeads Protein G (Novex by Life Technologies) at 4°C for 90 min. The245 
precipitates were washed five times with the same lysis buffer. The immunoprecipitated TNFR1246 
14
complex was eluted by incubation at 37°C for 40 min in 30 μl of TBS buffer containing 400 ng/μl247 
3× FLAG peptide (Sigma), and then analyzed by western blotting.248 
15
RESULTS 249 
IKK is effectively activated by linear polyubiquitin conjugated to NEMO, but not by250 
unanchored linear polyubiquitin.251 
To investigate in detail the roles of linear polyubiquitination of NEMO in IKK activation, we252 
established an in vitro IKK activation assay using purified proteins. In this assay,253 
baculovirus-purified IKK complex containing NEMO WT, or a NEMO mutant in which the critical254 
residues for ubiquitin-binding activity were mutated to Ala (R316A/R319A/E320A in human255 
NEMO, equivalent to R309A/R312A/E313A in mouse NEMO) (24), was incubated with256 
GST-IκBα (1–54), E1, E2, and ubiquitin in the presence or absence of LUBAC (Fig. 1A). When257 
incubated with the IKK complex containing NEMO WT, LUBAC generated unanchored linear258 
chains, conjugated these linear chains to NEMO, and promoted the phosphorylation of IκBα.259 
Phosphorylation of IκBα was also induced when a high concentration of IKK containing NEMO260 
WT was incubated without LUBAC, possibly due to partial activation of the IKK complex during261 
purification. However, in the presence of IKK complex containing NEMO R316A/R319A/E320A,262 
no detectable IKK activity was induced, although generation of unconjugated linear chains was not263 
affected by the mutation. Although the NEMO mutant was linearly ubiquitinated much more264 
weakly than NEMO WT, we could detect linear ubiquitination when a high concentration of the265 
NEMO mutant was incubated. These results indicated that the ubiquitin-binding activity of NEMO 266 
is involved in IKK activation, but it remains unclear why the linear ubiquitination of NEMO was267 
16
suppressed by the R316A/R319A/E320A mutation.268 
Both unanchored linear ubiquitin chains and linearly ubiquitinated NEMO were generated269
when IKK complex containing NEMO WT was activated (Fig. 1A). Therefore, to determine270 
whether unanchored linear ubiquitin chains and/or linearly ubiquitinated NEMO are involved in271 
IKK activation, we incubated E1, E2, LUBAC, and ubiquitin in the presence or absence of ATP,272 
followed by treatment with DTT, EDTA, and NEM to inactivate E1, E2, and LUBAC and 273 
disassemble E1- and UbcH5c-ubiquitin (Fig. 1B). After incubation with DTT to inactivate excess274 
NEM, and dialysis to remove NEM, DTT, and EDTA, the mixture was incubated with the IKK275 
complex and GST-IκBα (1–54) in the presence or absence of E1, E2, and LUBAC. IκBα 276 
phosphorylation was not induced when neither unanchored nor NEMO-conjugated linear chains277 
were generated (lanes 5–7), but efficient IκBα phosphorylation was observed in samples in which278 
both unconjugated and NEMO-conjugated linear chains were generated in the second-step reaction279 
(lanes 8–10). However, IκBα was not efficiently phosphorylated in samples in which unanchored280 
linear chains, but not NEMO-conjugated linear chains, were generated in the first-step reaction281 
(lanes 2–4). The unanchored linear chains generated in the first-step reaction appeared to be intact 282 
because they could bind the ubiquitin-binding domain of NEMO (data not shown); moreover, 283 
ubiquitin contains no Cys residues, and therefore cannot be modified by NEM. In our previous284 
analyses, unanchored linear diubiquitin weakly activated IKK in vitro (15). To confirm that linear285 
chains conjugated to NEMO activate the IKK complex much more efficiently than unanchored286 
17
linear polyubiquitin, and to determine the length of linear chains that is sufficient to activate IKK,287 
we incubated N-terminally His6-HA-tagged diubiquitin (His-HA-Ub2), instead of ubiquitin288 
monomers, in the presence or absence of E1, E2, and LUBAC (Fig. 1C). His-HA-Ub2 can be289 
recognized by the ubiquitin-binding domain of NEMO, and then conjugated to substrates, but290 
cannot generate linear chains longer than diubiquitin because of its N-terminal His6-HA tag (25).291 
Free His-HA-Ub2 did not overtly activate IKK (lanes 3–5), indicating that unanchored diubiquitin292 
cannot activate IKK effectively. However, IKK was effectively activated when His-HA-Ub2 was293 
conjugated to NEMO by LUBAC (lanes 6–8). This result confirmed that linear chains conjugated294 
to NEMO activate the IKK complex much more effectively than unanchored linear chains, and that295 
conjugation of linear diubiquitin to NEMO is sufficient to activate IKK.296 
 297
The HOIP NZF1 domain is involved in the recognition of NEMO by LUBAC.298 
Because ubiquitination often requires substrate binding by E3 enzymes (26), we hypothesized that299 
LUBAC may also recognize NEMO prior to linear polyubiquitination of the protein. To dissect the300 
molecular mechanism underlying linear polyubiquitination of NEMO, we probed the region of the301 
LUBAC ligase complex that is critical for recognition of NEMO. To this end, we first expressed302 
each subunit of LUBAC (HOIL-1L, HOIP, and SHARPIN) in HEK293T cells, with or without303 
NEMO. Consistent with our observations in a previous study (8), HOIP co-immunoprecipitated304 
with NEMO (Fig. 2A, lane 5). In the earlier study, deletion of the zinc finger region, containing the305 
18
zinc finger (ZF), NZF1, and NZF2 domains, attenuated the interaction between HOIP and NEMO,306 
although HOIP Δall-ZFs could still bind to NEMO when the two proteins were co-expressed with307 
HOIL-1L. By contrast, in this study, HOIP Δall-ZFs did not efficiently interact with NEMO even in 308 
the presence of HOIL-1L and SHARPIN (Figs. 2B and C, lane 4). The discrepancy between these309 
observations might be attributed to the amounts of plasmids used in the transfections: in the310 
previous study, we introduced larger amounts of the plasmids into cells than in this study.  311 
To precisely determine the roles played by the three domains of the HOIP ZF region in the312
interaction with NEMO, we co-transfected WT or mutant HOIP (Fig. 2B) into HEK293T cells313 
along with HOIL-1L, SHARPIN, and NEMO, and assessed the binding between NEMO and HOIP 314 
(Fig. 2C). Among the three domains in the zinc finger region, deletion of HOIP NZF1, but not315 
deletion of ZF or NZF2, attenuated NEMO binding (lanes 5–7). Conversely, among HOIP mutants316 
possessing only one of the three zinc finger domains, mutants containing NZF1, but not ZF or317 
NZF2, could bind NEMO (lanes 8–10). These results strongly indicated that HOIP NZF1 is318 
sufficient for the recognition of NEMO. To characterize the region of NEMO that is recognized by319 
HOIP, we introduced NEMO mutants into HEK293T cells together with HOIL-1L, HOIP, and320 
SHARPIN (data not shown); these experiments confirmed our previous observation (8) that321 
NEMO lacking the CoZi region failed to bind LUBAC.322 
 323
Crystal structure of NEMO CoZi in complex with HOIP NZF1.324 
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To obtain further insight into the recognition of NEMO by HOIP, we determined the crystal325 
structure of the complex between the NEMO CoZi and HOIP NZF1 domains (Table 1). The crystal 326 
structure contains one complex per asymmetric unit, in which NEMO and HOIP are present in 2:1327 
stoichiometry, i.e., each NEMO dimer binds one NZF1 molecule (Fig. 3A). Despite the328 
symmetrical surface on either side of NEMO, each NEMO dimer binds only one HOIP NZF1. This 329 
appears to be due to crystal packing effects, because another HOIP NZF1 of a symmetry-related330 
molecule occupies the second possible binding site on NEMO. This binding mode includes weak331 
interactions between NEMO and another surface of HOIP centered on residues Thr360 and Phe361,332 
which, according to our mutational analyses, are not biologically relevant (see below, Fig. 7C).333 
However, this observation does not exclude the possibility of symmetrical binding of two HOIP 334 
NZF1 molecules to NEMO in solution or in vivo, which might be influenced by factors such as the335 
local concentration of proteins (27). In the context of the full-length proteins, however, it seems336 
more likely that binding of a large LUBAC complex would hinder binding of a second HOIP NZF1337 
domain to a NEMO molecule. In fact, due to the transient nature of these interactions, to date we338 
have been unable to measure the stoichiometry of NEMO CoZi/HOIP NZF-1 binding using the339 
isolated domains in solution. 340 
In the crystal structure, HOIP NZF1 forms a compact structure typical of NZF domains (Fig.341
3A) (28), with a single zinc ion coordinated by four conserved cysteine residues: Cys356, Cys359,342 
Cys370, and Cys373. As shown previously, NEMO CoZi forms a coiled-coil homo-dimeric343 
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structure (19, 24). Although NEMO CoZi bound to HOIP NZF1 retains a conformation similar to344 
that of the free domain, the overall structures do not superimpose well, as indicated by the RMS345 
deviation of 2.6 Å for superimposition of the Cα atoms of residues 255–335 (Fig. 3B). This346 
structural difference appears to be due to the presence of a proline residue (Pro292) in the CoZi347 
domain, which introduces a kink into the coiled-coil structure (24). Consistent with this 348 
explanation, the two regions N-terminal and C-terminal to Pro292 (amino acids 255–291 and349 
293–335, respectively) superimpose more precisely (RMS deviation of 1.1 Å and 1.3 Å,350 
respectively) (Figs. 3C and D).  351 
The HOIP NZF1 binding site on NEMO is located on the CC2 domain, and covers a surface 352
area of 447.3 Å2. The binding region includes amino acid residues from Gln259 to Lys270 and353 
Glu264 to Asp275 on different protomers within the NEMO dimer (Figs. 3E and F). This surface is354 
located at the N terminus of NEMO CoZi and does not overlap with the ubiquitin-binding domain355 
(UBAN) (24). Thus, interaction with HOIP does not sterically hinder binding of NEMO to linear356 
ubiquitin chains (Fig. 3A).357 
A hydrophobic surface on the NZF1 domain, formed by the side chains of Ala366, Val368,358
Leu369, Pro376, Leu378, and Ala379, serves as the major interacting partner for NEMO by359 
contacting Ala263, Ala266, Leu267, Val268, and aliphatic portions of Gln259, Lys270, and360 
Gln271 (Figs. 3G and H). Furthermore, Glu374, Arg375, and Arg377 from HOIP are engaged in361 
electrostatic interactions with Lys270, Asp275, and Glu264, respectively. The Nε atom of NEMO362 
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Gln259 forms a hydrogen bond with the main-chain carbonyl oxygen of Ala365 (Fig. 3G).363 
Although it is not conserved among other NZF domains, the NEMO-binding surface on HOIP 364 
NZF1 is highly conserved among HOIP proteins from different species (Figs. 3I and J).365 
366
Gln271 and Asp275 of NEMO are involved in LUBAC-mediated linear polyubiquitination.367 
Our structural analysis indicated that Gln271 and Asp275 of mouse NEMO are involved in the368 
interaction with the HOIP NZF1 domain (Fig. 3). To confirm the importance of NEMO recognition369 
by HOIP in linear polyubiquitination of NEMO, we generated the NEMO mutants Q271A, D275A,370 
and Q271A/D275A and introduced them into HEK293T cells together with HOIP, HOIL-1L, and371 
SHARPIN. Whereas NEMO WT efficiently co-immunoprecipitated with HOIP, the interactions372 
between HOIP and the NEMO Q271A, D275A, and Q271A/D275A mutants were significantly373 
attenuated (Fig. 4A), suggesting that Gln271 and Asp275 of NEMO are involved in recognition by374 
HOIP in vivo. We also confirmed that NEMO Q271A/D275A could efficiently form the canonical375 
IKK complex with IKK1 and IKK2 (Fig. 4B). The ubiquitin-binding activity of NEMO plays376 
essential roles in NF-κB activation (24). Therefore, we compared the abilities of NEMO WT,377 
Q271A, D275A, and Q271A/D275A to bind linear and Lys63-linked polyubiquitins. All three of378 
these NEMO mutants interacted with both linear tetra-ubiquitin and Lys63-linked ubiquitin chains 379 
as efficiently as NEMO WT, which can bind both linear and Lys63 chains (longer than four380 
ubiquitin moieties) (Figs. 4C and D) (29). These results confirmed the finding that Gln271 and381 
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Asp275 are not located in the ubiquitin-binding domain of NEMO (Fig. 3A).382 
We next assessed the effect of Gln271 and/or Asp275 mutations of NEMO on its linear383
polyubiquitination in an in vitro ubiquitination assay, and found that NEMO Q271A/D275A was384 
not efficiently ubiquitinated by LUBAC (Fig. 4E). To confirm the attenuation of linear385 
polyubiquitination of NEMO mutants that failed to interact efficiently with HOIP in cells, we386 
introduced NEMO WT or mutants along with the components of LUBAC into HEK293T cells, and387 
then performed hot lysis to remove proteins non-covalently associated with NEMO (Fig. 4F).388 
Although NEMO WT was efficiently linearly polyubiquitinated by LUBAC, linear389 
polyubiquitination of NEMO Q271A, D275A, and Q271A/D275A was significantly attenuated.390 
 391
Involvement of both linear chain conjugation to NEMO and linear chain recognition by392 
NEMO in IKK activation.393 
Because the NEMO mutants (Q271A, D275A and Q271A/D275A) could not be recognized or394 
linearly polyubiquitinated by LUBAC, but could form IKK complexes with IKK1 and IKK2 and395 
bind to ubiquitin chains as well as NEMO WT, they appeared to be suitable tools for probing the396 
roles of linear polyubiquitination of NEMO in signal-induced NF-κB activation. We therefore397 
transiently introduced NEMO WT or mutants, together with the 5× NF-κB luciferase reporter, into398 
a NEMO-deficient subclone (N-1) of the Rat-1 fibroblast line. Luciferase assays revealed that the399 
Q271A, D275A, and Q271A/D275A mutations of NEMO attenuated IL-β-induced NF-κB400 
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activation (Fig. 5A, upper). The introduced NEMO WT and mutant proteins were expressed at401 
almost identical levels (Fig. 5A, lower) that were slightly lower than the level of endogenous402 
NEMO expression in the parental Rat-1 cells (data not shown). When NEMO WT or403 
Q271A/D275A was retrovirally introduced into the NEMO-defective N-1 cells, IL-1β-induced404 
linear polyubiquitination and IκBα phosphorylation were significantly attenuated by405 
Q271A/D275A mutation (Fig. 5B). We also stably introduced NEMO WT or Q271A/D275A into406 
the NEMO-deficient MEFs; these proteins were expressed at levels comparable to, or slightly407 
lower than, that of endogenous NEMO in WT MEFs (data not shown). In the NEMO-deficient408 
MEFs complemented with NEMO WT, treatment with TNF-α induced phosphorylation and409 
degradation of IκBα (Fig. 5C).  By contrast, in cells expressing NEMO Q271A/D275A,410 
TNF-α-mediated phosphorylation and degradation of IκBα were significantly attenuated (Fig. 5C).411 
Furthermore, TNF-α induced the IKK activity in anti-NEMO immunoprecipitates from cells412 
expressing NEMO WT, whereas TNF-α did not overtly induce IKK activity in NEMO413 
Q271A/D275A-expressing cells (Fig. 5D).414 
Lys278 and Lys302 of mouse NEMO, which are equivalent to Lys285 and Lys309 of415
human NEMO, are major sites of linear polyubiquitination by LUBAC (8). The UBAN motif, the416 
major ubiquitin-binding site of NEMO, preferentially binds to linear diubiquitin relative to417 
Lys63-linked diubiquitin. Within this motif, Phe305 is involved in the binding of both linear and418 
Lys63-linked diubiquitin, whereas Glu313 is specifically involved in linear diubiquitin recognition419 
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(24). To investigate the functional interaction between HOIP binding and linear polyubiquitination420 
of, or recognition of linear ubiquitin chains by, NEMO, we transiently expressed the NEMO421 
mutants indicated in Figure 6A in N-1 cells and assessed IL-1β-induced NF-κB activation by422 
luciferase assays. The introduced NEMO WT and mutants were expressed at almost identical423 
levels (Fig. 6A) that were slightly lower than the endogenous NEMO expression level in the424 
parental Rat-1 cells (data not shown). Introduction of mutations at the major polyubiquitination425 
sites, K278R/K302R (QDKK/AARR), into NEMO Q271A/D275A failed to further suppress426 
IL-1β-induced NF-κB activation attenuated by Q271A/D275A mutation, thus confirming that the427 
NEMO recognition by NZF1 of HOIP attenuates LUBAC-induced linear polyubiquitination of the428 
protein. Mutation of Glu313 to Ala (NEMO E313A) marginally suppresses NF-κB activation by429 
partially impairing linear chain binding (24), an observation confirmed in this study (Fig. 6A). To 430 
investigate whether impaired recognition of linear ubiquitin chains and NEMO would additively431 
suppress IL-1β-induced NF-κB activation, we generated NEMO Q271A/D275A/E313A 432 
(QD/AA/E313A). This triple mutant attenuated IL-1β-induced NF-κB activation to a greater433 
extent than NEMO Q271A/D275A or NEMO E313A. However, the NEMO F305A mutant, which434 
abolishes NEMO binding to both linear and Lys63-linked chains almost completely (24), strongly435 
suppressed IL-1β-induced NF-κB activation, confirming the importance of ubiquitin binding by436 
NEMO for NF-κB activation. These results suggested that conjugation of linear chains to NEMO,437 
and recognition of linear ubiquitin chains by NEMO, are synergistically involved in signal-induced438 
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NF-κB activation.439 
IKK2, a crucial kinase within the IKK complex that phosphorylates IκBα, homodimerizes440
via its kinase domain (KD), leading to activation of IKK via trans auto-phosphorylation (30). We 441 
examined the involvement of KD homodimerization of IKK2 in the activation of IKK provoked by442 
linearly ubiquitinated NEMO. Val229, His232, Tyr294, Gly295, and Pro296 of human IKK2 are443 
involved in the KD-KD interaction of IKK2 (30). Therefore, we mutated Val229 and His232 to Ala 444 
(V229A/H232A); in another construct, Tyr294, Gly295, and Pro296 were mutated to Leu, Lys, and445 
Gln, respectively, the corresponding amino acids in IKK1 (Y294L/G295K/P296Q) (30). IKK446 
becomes constitutively active when Ser177 and Ser181 in the activation loop of IKK2 are mutated447 
to phosphomimetic Glu (S177E/S181E) (30). IKK2 V229A/Y232A and Y294L/G295K/P296Q448 
with the S177E/S181E mutations can effectively phosphorylate IκBα (30), suggesting that both of449 
these IKK2 mutants can function as a kinase when specific Ser residues are phosphorylated.450 
NEMO-Ub2, a NEMO mutant with uncleavable linear di-ubiquitin at the C-terminus, mimics451 
linearly ubiquitinated NEMO, and the introduction of NEMO-Ub2 alone to HEK293T cells induces452 
IKK activation (15). With these observations in mind, we evaluated mutations of IKK2 that abolish453 
the KD-KD interaction upon NEMO-Ub2-mediated activation of IKK. Because IKK2 can be454 
activated even when transiently introduced alone (30), we introduced smaller amounts of IKK2455 
plasmids into HEK293T cells than in previous reports. As expected, under these assay conditions,456 
IKK2 WT or mutants were not activated when IKK2 was introduced alone (Fig. 6B). When457 
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introduced together with NEMO, IKK2 WT was weakly phosphorylated in its activation loop;458 
because IKK2 in NEMO-deficient cells is not effectively activated (31), this phosphorylation may459 
have been due to an IKK2-NEMO interaction. We have observed that NEMO-Ub2 induces460 
phosphorylation of IKK2 WT much more efficiently than NEMO. However, NEMO-Ub2 failed to 461 
induce phosphorylation of IKK2 V229A/Y232A or Y294L/G295K/P296Q, indicating that the462 
KD-KD interaction is necessary for the activation of IKK2 by NEMO-Ub2. Because IKK2463 
V229A/Y232A and Y294L/G295K/P296Q could form complexes with NEMO and NEMO-Ub2, as464 
well as IKK2 WT (Fig. 6C), these observations indicate that recognition of the linear chain465 
conjugated to NEMO, possibly by another NEMO molecule, plays crucial roles in IKK activation 466 
and subsequent NF-κB activation by inducing trans auto-phosphorylation of IKK2.467 
 468
The NEMO- and ubiquitin-binding activities of HOIP NZF1 are both involved in NF-κB469 
activation by LUBAC.470 
Our crystallographic analyses revealed that HOIP NZF1 is involved in NEMO recognition, and471 
that Arg369 in the NZF1 domain of mouse HOIP (equivalent to Arg375 in human HOIP, used for472 
the crystallographic analyses described above) contributes significantly to interaction with NEMO 473 
(Fig. 3G). However, NZF domains are classified as potential ubiquitin-binding modules (28, 32)474 
and HOIP NZF1 has also been reported to bind ubiquitin (11). The highly conserved TF/Φ motif of475 
NZF domains (Φ indicates a hydrophobic residue that is separated from TF (Thr-Phe) by ten476 
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residues (33)), is crucial for the ubiquitin-binding activity (33). Because Thr354 and Phe355 of477 
TF/Φ motif in mouse HOIP NZF1 (equivalent to Thr360 and Phe361 in human HOIP) are highly478 
conserved (Fig. 3J), it is reasonable to speculate that HOIP NZF1 might exhibit the479 
ubiquitin-binding activity as well as NEMO-binding activity. To confirm the ability of NZF1 to480 
bind ubiquitin, we generated the mouse HOIP NZF1 mutants R369A, T354A, F355A, and 481 
T354A/F355A. GST pull-down assays revealed that the T354A, F355A, and T354A/F355A 482 
mutations, but not R369A, attenuated binding of HOIP NZF1 to not only Lys63-linked diubiquitin483 
but also linear tetra-ubiquitin (Figs. 7A and B). To investigate the effect of T354A, F355A, and484 
T354A/F355A mutations on NEMO binding, we co-transfected HOIP WT or mutants into485 
HEK293T cells along with HOIL-1L, SHARPIN, and NEMO. HOIP WT, T354A, F355A, and486 
T354A/F355A efficiently co-immunoprecipitated with NEMO, whereas HOIP ΔNZF1 and R369A 487 
mutants failed to interact with NEMO (Fig. 7C). From these results, we draw the following488 
conclusions: NZF1 can bind to both ubiquitin and NEMO; Arg369 of HOIP NZF1 is involved in489 
NEMO recognition but not ubiquitin binding; and T354 and F355 are involved in ubiquitin490 
recognition but not NEMO binding. Furthermore, the in vitro binding assay using purified proteins 491 
revealed that NZF1 and Lys63-linked diubiquitin were both pulled down with MBP-NEMO,492 
indicating that NZF1 bound simultaneously to Lys63-linked diubiquitin and NEMO (Fig. 7D).  493 
To probe the roles of the ubiquitin- and NEMO-binding activities of NZF1 of HOIP in494
LUBAC-mediated NF-κB activation, we used luciferase assays to evaluate NF-κB activation495 
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mediated by exogenously introduced LUBAC. LUBAC-mediated NF-κB activation was496 
suppressed in HEK293T cells transfected with HOIP R369A or HOIP ∆NZF1. Introduction of497 
HOIP T354A/F355A also suppressed LUBAC-mediated NF-κB activation, but the suppression498 
was significantly weaker than that mediated by HOIP R369A (Fig. 7E). To further examine the499 
roles of the ubiquitin- and NEMO-binding activities of HOIP NZF1 in TNF-α-mediated NF-κB500 
activation, we introduced WT or HOIP mutants into HOIP Δlinear MEFs; the HOIP mutants were501 
expressed at levels identical to or a little higher than that of HOIP WT (data not shown). In cells502 
expressing HOIP R369A or T354A/F355A, IκBα degradation was slower than in HOIP 503 
WT-expressing cells; the extent of the delay in these two mutants was similar to that expressing504 
HOIP ΔNZF1 (Figs. 7F and G). The ubiquitin-binding activity of HOIP has been implicated in the505 
recruitment of LUBAC to the activated TNF-R1 signaling complex (TNF-RSC) (34). ΔNZF and506 
T354A/F355A mutations of HOIP attenuated TNF-α-induced recruitment of HOIP to TNF-RSC,507 
but the R369A mutation did not overtly suppress HOIP recruitment to the activated receptor508 
complex (Fig. 7H). Importantly, HOIP WT and R369A mutant were recruited to TNF-RSC at509 
similar levels, but ubiquitination of NEMO was significantly abrogated by the R369A mutation.510 
These results strongly indicated that NZF1 of HOIP can simultaneously bind both NEMO511
and ubiquitin, and that both interactions are involved in TNF-α-mediated NF-κB activation. Loss512 
of NEMO binding impairs linear polyubiquitination of NEMO, whereas loss of ubiquitin binding513 
impairs recruitment of LUBAC to TNF-RSC. However, loss of NEMO binding by HOIP NZF1514 
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appears to exert a more profound effect on LUBAC-mediated NF-κB activation than loss of515 
ubiquitin binding. Although the interaction between HOIP NZF1 and NEMO was abolished almost 516 
completely by the mutations described above, neither TNF-α- nor LUBAC-mediated NF-κB517 
activation was completely suppressed in cells expressing these mutants. We propose mechanisms 518 
that might underlie this residual NF-κB activation in the Discussion section.519 
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DISCUSSION520 
521
In this study, we showed that recognition of linear ubiquitin chains by NEMO and conjugation of522 
those chains to NEMO are synergistically involved in IKK activation. The IKK complex is523 
activated by phosphorylation of the IKK2 subunit (35). In general, phosphorylation of kinases is524 
mediated either by trans auto-phosphorylation or by upstream kinases (36). The crystal structure of 525 
Xenopus IKK2, determined recently, reveals that IKK2 contains a dimerization domain (31);526 
dimerization-defective IKK2 mutants fail to be activated. Furthermore, analysis of the crystal527 
structure of human IKK2 revealed that homotypic interaction of the IKK2 KD is crucial for IKK2528 
activation (30). We also showed here that IKK2 mutants that are defective in KD-KD interaction529 
could not be activated by NEMO-Ub2, which mimics linearly ubiquitinated NEMO. These results530 
strongly indicate that IKK2 activation mediated by linear chains requires trans 531 
auto-phosphorylation; thus it seems plausible that linear chains conjugated to NEMO by LUBAC532 
are recognized by NEMO in trans on another IKK complex, thereby inducing multimerization of 533 
IKK complexes. Upon multimerization, IKK2 could dimerize and trans auto-phosphorylate (Fig.534 
8). It is possible that binding of ubiquitin to the UBAN domain induces conformational changes in535 
NEMO, thereby changing the positions of IKK1 and IKK2, leading to phosphorylation of IKK2.536 
However, considering the results of structural analyses of IKK2, together with our observations,537 
the former scenario seems more likely (37).538 
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We have probed the interactions between HOIP and NEMO by solving a co-crystal539 
structure of NZF1 of human HOIP and CoZi of mouse NEMO while our mutational studies have540 
been performed using mouse HOIP. However, the surface residues from HOIP that interact with541 
NEMO are fully conserved in human and mouse species (Fig. 3J). Our mutational analyses based542 
on the structure of the co-crystal show that direct recognition of NEMO by HOIP plays a major role 543 
in NF-κB activation following conjugation of linear chains to NEMO. Although the544 
RING-IBR-RING region of HOIP is the catalytic center for linear polyubiquitination by LUBAC545 
(7), recent results obtained using an in vitro ubiquitin assay have suggested that the RING2 domain546 
of HOIL-1L plays a role in linear polyubiquitination of NEMO (38). However, given that the547 
HOIP-SHARPIN complex effectively linearly polyubiquitinates NEMO in vitro and activates548 
NF-κB in cells (12), any involvement of the RING2 domain of HOIL-1L in linear549 
polyubiquitination of NEMO and NF-κB activation seems likely to be marginal. Thus, HOIP plays550 
central roles in LUBAC-mediated NF-κB activation via direct recognition of linear polyubiquitin551 
and conjugation of this molecule to NEMO. However, neither NF-κB activation nor linear 552 
polyubiquitination of NEMO was completely abolished in NEMO Q271A/D275A, which evades553 
recognition by LUBAC. We suspect that the residual activation might be caused by the presence of554 
one or more additional NEMO recognition sites. Consistent with this idea, the NEMO-LUBAC555 
interaction cannot be completely abolished by mutations in HOIP NZF1, although HOIP NZF1556 
does appear to be the primary NEMO recognition site. In support of this possibility, in our previous557 
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report (8), we observed that HOIP lacking NZF1 could bind NEMO in the presence of high levels558 
of HOIL-1L. Alternatively, in light of observations that the linear polyubiquitination activity of 559 
LUBAC is dispensable for NF-κB activation via B-cell antigen receptor (39), residual NF-κB560 
activation might be mediated by other IKK activation pathways. The kinase TAK1 has been561 
suggested to activate IKK2 (40); specifically, TAK1-mediated IKK activation has been proposed to562 
involve the Lys63 chain-binding activity of TAB2 and TAB3, which form a complex with TAK1563 
(41). Recently, Lys63 and linear hybrid chains have been implicated in IKK activation (42). It is564 
hypothesized that both the TAK1 and IKK complexes bind simultaneously to one hybrid chain565 
composed of Lys63 and linear linkages, generated upon IL-1β stimulation, thereby inducing566 
phosphorylation of IKK2 (42). In addition to the UBAN motif that preferentially binds linear567 
chains, NEMO possesses another ubiquitin-binding domain, the ZF domain, in its C-terminus.568 
NEMO can bind longer Lys63-linked chains by utilizing both the UBAN and ZF domains,569 
potentially inducing IKK activation by multimerizing the IKK complex. Because the570 
NEMO-LUBAC interaction appears dispensable for the generation of the Lys63 and Lys63/linear571 
hybrid chains, the residual NF-κB activation in NEMO Q271A/D275A-expressing cells might be572 
attributed to these ubiquitin chains, as distinct from linear chains. However, considering our results573 
described here, together with the previous observation that Lys63-linked chains are dispensable for574 
TNF-α-mediated NF-κB activation (43), it seems likely that linear chain-mediated trans 575 
auto-phosphorylation of IKK2 plays a major role in NF-κB activation, at least in the case of576 
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activation mediated by the TNF receptor family. In further support of this notion, we observed577 
previously that CD40-mediated NF-κB activation is almost completely abolished in B-cells from578 
mice lacking the linear polyubiquitination activity of LUBAC (39). Further dissection of the579 
mechanism underlying IKK activation via LUBAC-mediated linear polyubiquitination will be580 
needed to clarify the involvement of linear chain-mediated dimerization of IKK2 in NF-κB581 
activation induced by various stimuli, including IL-1β.582 
We also showed here that HOIP NZF1 simultaneously binds NEMO and ubiquitin (Fig.583
7D). The TF/Φ motifs of the HOIP NZF domains, which are crucial for ubiquitin binding by NZFs,584 
are highly conserved. Consistent with this, the T354A, F355A, and T354A/F355A mutants of585 
HOIP NZF1 failed to bind ubiquitin. By contrast, NZF1 R369A could bind ubiquitin as efficiently586 
as WT NZF1 (Figs. 7A and B). Recruitment of LUBAC to TNF-RSC upon TNF-α stimulation is a587 
prerequisite for TNF-α-mediated NF-κB activation, and the ubiquitin-binding activity of LUBAC588 
is required for this recruitment (34). We observed in this study that the T354A/F355A double589 
mutation, but not the R369A mutation, of HOIP attenuated TNF-α-induced recruitment of HOIP to590 
TNF-RSC (Fig. 7H). Furthermore, we observed that both HOIP R369A and T354A/F355A 591 
attenuated TNF-α-induced NF-κB activation at a level comparable to that of HOIP ΔNZF1 when592 
expressed in HOIP Δlinear MEFs (Figs. 7F and G). However, the luciferase assays revealed that593 
HOIP R369A, but not T354A, F355A, or T354A/F355A, significantly suppressed NF-κB594 
activation induced by the introduction of LUBAC components (Fig. 7E). Recruitment of LUBAC595 
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to TNF-RSC is a prerequisite for TNF-α-mediated NF-κB activation, but is apparently not required596 
for NF-κB activation provoked by the exogenous introduction of LUBAC components; this may597 
explain why the R369A mutation of HOIP suppressed LUBAC-mediated NF-κB activation more598 
severely than the T354A/F355A mutation.599 
In summary, we dissected the roles of linear polyubiquitination in NF-κB activation and600
showed that recognition of linear polyubiquitin conjugated to NEMO, possibly by NEMO in601 
another IKK complex, induces trans auto-phosphorylation of IKK2 and subsequent activation of602 
NF-κB. The NZF1 domain of HOIP is involved in the linear polyubiquitination of NEMO by603 
recognizing NEMO, leading to the homo-dimerization of IKK2. In addition to NEMO recognition,604 
HOIP NZF1 plays another role in signal-induced NF-κB activation: the recruitment of LUBAC to605 
the activated receptor complexes via its ubiquitin-binding activity (Fig. 8). Amino acid residues606 
crucial for ubiquitin binding are conserved in HOIP NZF1 (Fig. 3I), whereas other residues are not 607 
conserved in other human NZFs. By contrast, the NEMO-binding surface on HOIP NZF1 is highly 608 
conserved in NZF1s of vertebrate HOIP proteins (Fig. 3J). Because HOIP NZF1 can bind to both609 
ubiquitin and NEMO simultaneously (Fig. 7D), we conclude that HOIP NZF1 plays a critical role610 
in signal-induced activation by recruiting LUBAC to the site of function and ubiquitinating611 
substrate to activate NF-κB on site.612 
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Accession code. Atomic coordinates and structure factors of the NEMO CoZi/HOIP NZF1614 
complex structure have been deposited in the Protein Data Bank under accession code 4O4M.615 
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FIGURE LEGENDS 749 
 750
FIGURE 1. Linearly ubiquitinated NEMO activates the IKK complex more efficiently than751 
unanchored linear ubiquitin chains. (A) IKK complex (0.5, 2.5 or 5 μg/ml) and either NEMO WT 752 
or R316A/R319A/E320A was incubated for 1 h at 30°C with GST-IκBα (1–54), E1, and UbcH5c753 
in the presence or absence of LUBAC, and the reaction mixtures were probed with the indicated754 
antibodies. (B) Reaction mixtures containing E1, E2, LUBAC, and ubiquitin were incubated with755 
or without ATP. After incubation, E1, E2, and LUBAC were inactivated with EDTA and NEM, and756 
the reaction mixtures were dialyzed. The dialyzed samples were incubated with GST-IκBα (1–54)757 
and the IKK complex in the presence or absence of E1, E2, and LUBAC, followed by probing with758 
the indicated antibodies. (C) His-HA-Ub2 (10, 50, or 250 μg/ml) or 250 μg/ml ubiquitin was759 
incubated with E1, UbcH5c, LUBAC, IKK complex, and GST-IκBα (1–54), followed by probing760 
with the indicated antibodies. 761 
 762
FIGURE 2. The NZF1 domain of HOIP is responsible for NEMO binding. (A) Myc-HOIP,763 
Myc-HOIL-1L, or Myc-SHARPIN were transfected into HEK293T cells with or without764 
FLAG-NEMO, and cell lysates and anti-FLAG immunoprecipitates were immunoblotted with the765 
indicated antibodies. (B) Schematics of HOIP and its mutants. (C) HA-HOIP and its mutants, along766 
with Myc-HOIL-1L, T7-SHARPIN, and FLAG-NEMO, were transfected into HEK293T cells.767 
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Cell lysates (top) and anti-HA immunoprecipitates (bottom) were immunoblotted with the768 
indicated antibodies.769 
 770
FIGURE 3. Structure of the NEMO CoZi in complex with HOIP NZF1. (A) Overall structure of771 
the NEMO CoZi/HOIP NZF1 complex. The two chains of NEMO are colored in yellow and green;772 
HOIP is shown in salmon. The coiled-coil2 and LZ (CoZi) and UBAN (ubiquitin-binding in ABIN 773 
proteins and NEMO) domains are indicated on the NEMO structure. (B to D) Superposition of the774 
NEMO molecules in the free form (light orange) and in complex with HOIP NZF1 (green),775 
including residues (B) 255–335, (C) 255–291, and (D) 293–335. Arrows indicate position of the776 
Pro292 residues in the NEMO structure. (E and F) Amino acid residues involved in the interactions 777 
are indicated on the surfaces of NEMO (E) and HOIP (F). (G) Stereo view of the interactions778 
between NEMO CoZi and HOIP NZF1. Interacting amino acids are shown as sticks. Salt bridges779 
and hydrogen bonds are indicated with dashed lines. (H) Open-book representation of NEMO780 
recognition by HOIP NZF1. (I) Analysis of conservation of residues of HOIP NZF1 involved in781 
binding to NEMO in different NZF domain-containing proteins. Interacting residues from HOIP 782 
NZF1 and conserved residues are highlighted in red. (J) Analysis of conservation of residues of783 
HOIP NZF1 involved in binding to NEMO in various species. Highly conserved residues are784 
highlighted in dark gray, and less conserved residues in light gray. The red arrows indicate residues785 
from human HOIP that interact with NEMO.786 
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 787
FIGURE 4. Involvement of Gln271 and Asp275 of NEMO in LUBAC-mediated linear788 
polyubiquitination. (A) HEK293T cells were transfected as indicated, and cell lysates (top),789 
anti-FLAG immunoprecipitates (middle), and anti-HA immunoprecipitates (bottom) were790 
immunoblotted. (B) HEK293T cells were transfected as indicated, and cell lysates (bottom) and791 
anti-FLAG immunoprecipitates (top) were immunoblotted. (C and D) NEMO WT or mutants792 
fused with MBP were incubated with linear tetra-ubiquitin (C) or K63 chains (D) followed by793 
pull-down with maltose resins. (E) MBP-NEMO WT or Q271A/D275A was incubated as indicated794 
at 37°C for 1 h, followed by immunoblotting with anti-MBP antibody. (F) FLAG-NEMO or its795 
mutants were introduced into HEK293T cells together with LUBAC. Cells were subjected to hot796 
lysis, and anti-FLAG immunoprecipitates were probed with anti-linear ubiquitin or anti-FLAG797 
antibody.798 
 799
FIGURE 5. Conjugation of linear chains to NEMO plays crucial roles in IKK activation. (A)800 
NEMO-defective N-1 cells were transiently transfected with 5× NF-κB luciferase reporter and801 
NEMO WT or mutants. At 16 h after transfection, cells were treated with IL-1β (1 ng/ml) for 8 h,802 
and luciferase activity was measured (mean ± SEM; n=3). The amounts of NEMO and tubulin803 
were also assessed. (B) N-1 cells expressing NEMO WT or Q271A/D275A were treated with804 
IL-1β (20 ng/ml) for the indicated periods, and anti-NEMO immunoprecipitates were805 
46
immunoblotted. (C) NEMO-deficient MEFs stably expressing NEMO WT or Q271A/D275A were806 
treated with TNF-α (10 ng/ml) for the indicated periods, and cell lysates were immunoblotted with807 
the indicated antibodies. (D) Anti-NEMO immunoprecipitates from NEMO-deficient MEFs stably808 
expressing NEMO WT or Q271A/D275A treated with TNF-α (10 ng/ml) for the indicated periods 809 
were incubated with GST-IκBα (1–54) at 30°C for 2 h. The reaction mixtures were probed with the 810 
indicated antibodies.811 
 812
FIGURE 6. Mechanism underlying IKK activation mediated by LUBAC. (A) NEMO-defective813 
N-1 cells were transiently transfected with 5× NF-κB luciferase reporter and NEMO WT or814 
mutants. At 16 h after transfection, cells were treated with IL-1β (1 ng/ml) for 8 h, and luciferase815 
activity was measured (mean ± SEM n=3). The amounts of NEMO and tubulin were also assessed.816 
(B) FLAG-IKK2 or its mutants, along with FLAG-NEMO or FLAG-NEMO-Ub2, were transfected 817 
into HEK293T cells; cell lysates were immunoblotted with the indicated antibodies. (C)818 
FLAG-IKK2 and its mutants, along with FLAG-NEMO or FLAG-NEMO-Ub2, were transfected819 
into HEK293T cells and cell lysates (left); anti-NEMO immunoprecipitates (right) were820 
immunoblotted as indicated.821 
 822
FIGURE 7. Simultaneous recognition of NEMO and ubiquitin by HOIP NZF1 is required for823 
NF-κB activation. (A and B) WT or mutant HOIP NZF1 fused to GST was incubated with K63824 
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diubiquitin (A) or linear tetra-ubiquitin (B) as indicated, followed by pull-down with glutathione825 
beads. Bound proteins were probed as indicated. (C) HA-HOIP or its mutants were transfected into826 
HEK293T cells along with Myc-HOIL-1L, T7-SHARPIN, and FLAG-NEMO, and cell lysates827 
(left) and anti-FLAG immunoprecipitates (right) were immunoblotted as indicated. (D) Full-length828 
NEMO fused with MBP was incubated with K63-diubiquitin and GST-NZF1, followed by 829 
pull-down with maltose resins. Bound proteins were probed as indicated. (E) Luciferase activities830 
in HEK293T cells expressing HA-HOIP WT or mutants, along with Myc-HOIL-1L, T7-SHARPIN, 831 
and 5× NF-κB luciferase reporter, are shown relative to the activity in cells expressing LUBAC832 
WT, defined as 100% (mean ± SEM; n=3). (F and G) HOIP Δlinear MEFs retrovirally expressing833 
HOIP WT, ΔNZF1, R369A (F) or T354A/F355A (G) were treated with TNF-α (3 ng/ml) for the834 
indicated periods and probed with the indicated antibodies. (H) HOIP Δlinear MEFs retrovirally835 
expressing HOIP WT, ΔNZF1, R369A or T354A/F355A were treated with FLAG-His6-TNF-α 836 
(FH- TNF-α) (3 μg/ml) for the indicated periods; cell lysates (bottom) and anti-FLAG837 
immunoprecipitates (top) were immunoblotted as indicated.838 
 839
FIGURE 8. Schematic representation of LUBAC-mediated IKK and NF-κB activation. Upon840 
ligand stimulation, LUBAC is recruited to the receptor via the ubiquitin-binding ability of HOIP 841 
NZF1. Then, HOIP NZF1 also recognizes NEMO, and this recognition is involved in linear842 
polyubiquitination of NEMO. Linear chains conjugated to NEMO are recognized by NEMO in 843 
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trans on another IKK complex, thereby inducing multimerization of the IKK complex and trans 844 
auto-phosphorylation of IKK2.845 
49
Table 1. Data collection and refinement statistics.846 
847
NEMO CoZi/HOIP NZF1 complex848
849
Data collection850 
Space group P65 851 
Cell dimensions                     852 
   a, b, c (Å) 81.46, 81.46, 74.57853
   α, β, γ (°) 90.00, 90.00, 120.00854
Wavelength (Å) 1.282855 
Resolution (Å) 33.0–2.00 (2.05–2.00)a 856 
Rmerge 0.14 (1.11) 857 
I/σI 7.7 (1.1) 858 
Completeness (%) 83.1 (66.6) 859 
Redundancy 7.6 (6.8)860 
CC ½                                                            0.99 (0.63) 861 
 862
Refinement 863 
Resolution (Å) 50.00–2.00864 
No. reflections 17945 865 
Rwork/Rfree b 25.9/31.3866
No. atoms 1,743 867 
Protein 1,642868 
Water 100869 
Ion 1870 
B-factors 871 
Protein                                                         34.4 872 
Water 36.6873 
Ion 20.6874 
R.m.s. deviation875 
Bond lengths (Å) 0.011876 
Bond angles (°)                                           1.369877 
Ramachandran Statistics 878 
Residues in most favored regions 97.3%879 
Residues in additionally allowed regions      2.7%880 
Residues in generously allowed regions     0.0%881 
50
Residues in disallowed regions 0.0%882 
883
a
The values in parenthesis relate to the highest-resolution shells. 
b
Rfree was calculated for a884
randomly chosen 5% of reflections; the R factor was calculated for the remaining 95% of885 
reflections. 886 
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